236 related articles for article (PubMed ID: 24370995)
21. Action of YM155 on clear cell renal cell carcinoma does not depend on survivin expression levels.
Sim MY; Huynh H; Go ML; Yuen JSP
PLoS One; 2017; 12(6):e0178168. PubMed ID: 28582447
[TBL] [Abstract][Full Text] [Related]
22. Small-molecule survivin inhibitor YM155 enhances radiosensitization in esophageal squamous cell carcinoma by the abrogation of G2 checkpoint and suppression of homologous recombination repair.
Qin Q; Cheng H; Lu J; Zhan L; Zheng J; Cai J; Yang X; Xu L; Zhu H; Zhang C; Liu J; Ma J; Zhang X; Dai S; Sun X
J Hematol Oncol; 2014 Aug; 7():62. PubMed ID: 25139395
[TBL] [Abstract][Full Text] [Related]
23. Survivin inhibitor YM155 induces mitochondrial dysfunction, autophagy, DNA damage and apoptosis in Bcl-xL silenced glioma cell lines.
Jane EP; Premkumar DR; Sutera PA; Cavaleri JM; Pollack IF
Mol Carcinog; 2017 Apr; 56(4):1251-1265. PubMed ID: 27805285
[TBL] [Abstract][Full Text] [Related]
24. Interleukin enhancer-binding factor 3/NF110 is a target of YM155, a suppressant of survivin.
Nakamura N; Yamauchi T; Hiramoto M; Yuri M; Naito M; Takeuchi M; Yamanaka K; Kita A; Nakahara T; Kinoyama I; Matsuhisa A; Kaneko N; Koutoku H; Sasamata M; Yokota H; Kawabata S; Furuichi K
Mol Cell Proteomics; 2012 Jul; 11(7):M111.013243. PubMed ID: 22442257
[TBL] [Abstract][Full Text] [Related]
25. YM155 inhibits tumor growth and enhances chemosensitivity to cisplatin in osteosarcoma.
Gao JZ; Chen FH; Wang L; Wei H; Meng SL
Eur Rev Med Pharmacol Sci; 2015; 19(11):2062-9. PubMed ID: 26125270
[TBL] [Abstract][Full Text] [Related]
26. YM155, a small molecule inhibitor of survivin expression, sensitizes cancer cells to hypericin-mediated photodynamic therapy.
Gyurászová K; Mikeš J; Halaburková A; Jendželovský R; Fedoročko P
Photochem Photobiol Sci; 2016 Jun; 15(6):812-21. PubMed ID: 27241169
[TBL] [Abstract][Full Text] [Related]
27. Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models.
Nakahara T; Kita A; Yamanaka K; Mori M; Amino N; Takeuchi M; Tominaga F; Kinoyama I; Matsuhisa A; Kudou M; Sasamata M
Cancer Sci; 2011 Mar; 102(3):614-21. PubMed ID: 21205082
[TBL] [Abstract][Full Text] [Related]
28. The survivin suppressant YM155 potentiates chemosensitivity to gemcitabine in the human pancreatic cancer cell line MiaPaCa-2.
Yoon DH; Shin JS; Jin DH; Hong SW; Jung KA; Kim SM; Hong YS; Kim KP; Lee JL; Suh C; Lee JS; Kim TW
Anticancer Res; 2012 May; 32(5):1681-8. PubMed ID: 22593446
[TBL] [Abstract][Full Text] [Related]
29. Autophagic HuR mRNA degradation induces survivin and MCL1 downregulation in YM155-treated human leukemia cells.
Chiou JT; Lee YC; Huang CH; Shi YJ; Wang LJ; Chang LS
Toxicol Appl Pharmacol; 2020 Jan; 387():114857. PubMed ID: 31837377
[TBL] [Abstract][Full Text] [Related]
30. Cellular inhibitor of apoptosis protein 1 (cIAP1) stability contributes to YM155 resistance in human gastric cancer cells.
Jung SA; Park YM; Hong SW; Moon JH; Shin JS; Lee HR; Ha SH; Lee DH; Kim JH; Kim SM; Kim JE; Kim KP; Hong YS; Choi EK; Lee JS; Jin DH; Kim T
J Biol Chem; 2015 Apr; 290(16):9974-85. PubMed ID: 25635055
[TBL] [Abstract][Full Text] [Related]
31. YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer.
Yamanaka K; Nakata M; Kaneko N; Fushiki H; Kita A; Nakahara T; Koutoku H; Sasamata M
Int J Oncol; 2011 Sep; 39(3):569-75. PubMed ID: 21674125
[TBL] [Abstract][Full Text] [Related]
32. YM155 reverses rapamycin resistance in renal cancer by decreasing survivin.
Koike H; Nitta T; Sekine Y; Arai S; Furuya Y; Nomura M; Matsui H; Shibata Y; Ito K; Oyama T; Suzuki K
J Cancer Res Clin Oncol; 2014 Oct; 140(10):1705-13. PubMed ID: 24916171
[TBL] [Abstract][Full Text] [Related]
33. YM155 induces EGFR suppression in pancreatic cancer cells.
Na YS; Yang SJ; Kim SM; Jung KA; Moon JH; Shin JS; Yoon DH; Hong YS; Ryu MH; Lee JL; Lee JS; Kim TW
PLoS One; 2012; 7(6):e38625. PubMed ID: 22723871
[TBL] [Abstract][Full Text] [Related]
34. Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines.
Iwasa T; Okamoto I; Suzuki M; Nakahara T; Yamanaka K; Hatashita E; Yamada Y; Fukuoka M; Ono K; Nakagawa K
Clin Cancer Res; 2008 Oct; 14(20):6496-504. PubMed ID: 18927289
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of survivin reduces HIF-1α, TGF-β1 and TFE3 in salivary adenoid cystic carcinoma.
Wang YF; Ma SR; Wang WM; Huang CF; Zhao ZL; Liu B; Zhang WF; Zhao YF; Zhang L; Sun ZJ
PLoS One; 2014; 9(12):e114051. PubMed ID: 25485635
[TBL] [Abstract][Full Text] [Related]
36. Reactive oxygen species and autophagy associated apoptosis and limitation of clonogenic survival induced by zoledronic acid in salivary adenoid cystic carcinoma cell line SACC-83.
Ge XY; Yang LQ; Jiang Y; Yang WW; Fu J; Li SL
PLoS One; 2014; 9(6):e101207. PubMed ID: 24963720
[TBL] [Abstract][Full Text] [Related]
37. Small molecule inhibitor YM155-mediated activation of death receptor 5 is crucial for chemotherapy-induced apoptosis in pancreatic carcinoma.
Zhao X; Puszyk WM; Lu Z; Ostrov DA; George TJ; Robertson KD; Liu C
Mol Cancer Ther; 2015 Jan; 14(1):80-9. PubMed ID: 25344582
[TBL] [Abstract][Full Text] [Related]
38. TAT-IL-24-KDEL-induced apoptosis is inhibited by survivin but restored by the small molecular survivin inhibitor, YM155, in cancer cells.
Zhang J; Xu R; Tao X; Dong Y; Lv X; Sun A; Wei D
Oncotarget; 2016 Jun; 7(24):37030-37042. PubMed ID: 27203744
[TBL] [Abstract][Full Text] [Related]
39. Small Molecule Survivin Inhibitor YM155 Displays Potent Activity Against Human Osteosarcoma Cells.
Zhang S; Wang X; Gu Z; Wang L
Cancer Invest; 2016 Sep; 34(8):401-7. PubMed ID: 27559851
[TBL] [Abstract][Full Text] [Related]
40. The over-expression of survivin enhances the chemotherapeutic efficacy of YM155 in human hepatocellular carcinoma.
Xia H; Chen J; Shi M; Deivasigamani A; Ooi LL; Hui KM
Oncotarget; 2015 Mar; 6(8):5990-6000. PubMed ID: 25714025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]